Loading
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Latest filing published 18 Aug 2022 for Palisade Bio, INC., €9,832. Read the official filing
Filing timeline
BuySaleThomas Hallam
Insider track record
Disclosed buys
3
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-53.1%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Thomas Hallam: trading record in brief
This profile gathers the share dealings of Thomas Hallam in Palisade Bio, Inc. Over a trading history stretching from 21 September 2021 to 16 August 2022, the count stands at 3 filings.
Purchases make up the whole of the open-market record (3 purchases, €33k). Unlike grants, an open-market purchase is paid for by the insider, at the market price. So far in 2022, the count stands at 2 purchases and no sales.
A typical purchase (the median) is worth €11k. On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.
On 18 August 2022 came the latest disclosure, an open-market purchase for €9,832 in Palisade Bio, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Thomas Hallam
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
40,000 shares@ US$0.2521.3% of flowCommon Stock, par value $0.01SEC:0001493152-22-023511:0
Canonical exit: 14 Nov 2022 (T+90)
10,000 shares@ US$1.1832.2% of flowCommon StockSEC:0001209191-22-021405:0
Canonical exit: 26 Jun 2022 (T+90)
6,000 shares@ US$2.4938.3% of flowCommon StockSEC:0001209191-21-057318:0
Canonical exit: 20 Dec 2021 (T+90)
3 of 3 declarations
